BioSpace News Archive

Drug Development

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Kura Oncology, Inc. today announced that the first patient has been dosed in KOMET-008, the Company’s Phase 1 trial of its menin inhibitor ziftomenib, in combination with gilteritinib, FLAG-IDA or LDAC for the treatment of NPM1-mutant or KMT2A-rearranged acute myeloid leukemia (AML).

February 26, 2024

·

7 min read

Genetown

Agenus to Participate in Leerink Partners Global Biopharma Conference

Agenus Inc. today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Leerink Global Biopharma Conference on March 11th - 13th in Miami Beach, Florida.

February 26, 2024

·

1 min read

Pharm Country

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported new analyses from the positive Phase 3 SIERRA trial of Iomab-B in oral presentations at the at the 2024 Tandem Meetings.

February 26, 2024

·

6 min read

Genetown

Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences

Fusion Pharmaceuticals Inc. today announced that the Company will participate in two upcoming investor conferences.

February 26, 2024

·

2 min read

Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference

Daxor Corporation today announces it will be exhibiting at the Technology and Heart Failure Therapeutics Conference (THT), which brings together the world’s leading experts in heart failure innovations at the Westin Boston Seaport in Boston, Massachusetts March 4-6, 2024.

February 26, 2024

·

3 min read

BioMidwest

Latest EnsoData FDA 510(k) Clearance Enables AI-Powered Sleep Diagnosis Using Pulse Oximetry Devices

EnsoData, a pioneer in healthcare AI, achieved FDA 510(k) clearance for groundbreaking technology that enables AI-powered sleep diagnosis using FDA-cleared pulse oximetry (pulse ox) devices.

February 26, 2024

·

4 min read

Pharm Country

PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) today announced that David Mack, Ph.D., President and Chief Executive Officer of PMV Pharmaceuticals, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference taking place in Boston, Massachusetts March 4-6, 2024.

February 26, 2024

·

1 min read

Business

Armonica Technologies announces Emily Milsovic joins Board of Directors

Armonica Technologies, Inc., a pioneer in sample-prep free direct optical DNA sequencing, announced the appointment of biotech veteran Emily Milsovic to the Board of Directors.

February 26, 2024

·

2 min read

Drug Development

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

Boehringer Ingelheim announced that up to 83.0% of adults treated with survodutide (BI 456906) achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%) in a Phase II trial [response difference: 64.8% (CI 51.1% - 78.6%), p<0.0001].

February 26, 2024

·

15 min read

Genetown

BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

BeiGene, Ltd. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending approval of tislelizumab as a treatment for non-small cell lung cancer across three indications.

February 26, 2024

·

9 min read